-
Five prime new drug combined with opdivo pancreatic cancer phase 2 clinical failure!
Time of Update: 2020-02-19
Compiling coco The idea that five prime therapeutics combines its experimental CSF-1 receptor inhibitor, cabiralizumab, with the checkpoint inhibitor of BMS, opdivo, to treat pancreatic cancer is bank
-
For the treatment of advanced non-small cell lung cancer, AstraZeneca PD-1/TIGIT bispecific antibody initiates phase 2 clinical trial
Time of Update: 2023-01-05
▲If you have any business needs, please press and hold to scan the QR code above, or▎WuXi AppTec Content Team Editor Recently, AstraZeneca launched a Phase 2 clinical trial for its PD-1/ The TIGIT bispecific antibody AZD2936 was evaluated for its efficacy and safety in the treatment of patients with stage 3 unresectable or stage 4 non-small cell lung cancer (NCSLC).
-
ASCO: Phase 2 study of continuous talazopanib (TALA) plus intermittent low-dose temozolomide (TMZ
Time of Update: 2022-08-10
TALA plus TMZ treatmentThe primary outcome measure was objective response rate (ORR) based on RECIST 1.
TALA plus TMZ treatmentThe primary outcome measure was objective response rate (ORR) based on RECIST 1.
TALA plus TMZ treatmentThe primary outcome measure was objective response rate (ORR) based on RECIST 1.
-
Pancreatic cancer double immune + radiotherapy phase 2 trial achieved good results
Time of Update: 2022-05-28
Lancet Oncol: Quality of life analysis from the CLEAR study showed that patients with advanced renal cell carcinoma who received lenvatinib plus pembrolizumab had similar or better quality of life scores than sunitinib, especially in the time to final disease progression .
-
Positive Phase 2 Clinical Results of LAG-3 Therapy for Non-Small Cell Lung Cancer
Time of Update: 2022-04-22
"References:[1] Immutep's efti in combination with MSD's pembrolizumab shows encouraging antitumor activity in difficult to treat 2nd line metastatic lung cancer patients.
-
Veliparib Maintenance Therapy Improves Outcomes in Patients With BRCA1/2 Germline Mutated Breast Cancer
Time of Update: 2022-03-04
The phase III BROCADE3 study showed that adding veliparib to carboplatin/paclitaxel improved PFS in patients with advanced HER2-negative, BRCA1/2 germline-mutated breast cancer (HR=0.
The phase III BROCADE3 study showed that adding veliparib to carboplatin/paclitaxel improved PFS in patients with advanced HER2-negative, BRCA1/2 germline-mutated breast cancer (HR=0.
-
Gritstone bio's innovative cancer vaccine enters phase 2/3 clinical trial
Time of Update: 2022-02-23
References:[1] Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC).
-
100% disease control rate in express pancreatic cancer and gastrointestinal cancer patients, positive phase 2 clinical results of KRAS inhibitor
Time of Update: 2022-02-21
In a cohort of previously treated patients with pancreatic ductal adenocarcinoma and other gastrointestinal (GI) cancers harboring a KRAS G12C mutation, adagrasib demonstrated significant clinical activity and broad disease control .
"Reference: [1] Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers.
-
KRAS Inhibitors: Positive Phase 2 Results in Pancreatic and Gastrointestinal Cancers
Time of Update: 2022-02-19
In a cohort of previously treated patients with pancreatic duct adenocarcinoma and other gastrointestinal (GI) cancers with KRAS G12C mutation, adagasib demonstrated significant clinical activity and broad disease control .
-
100% disease control rate in patients with pancreatic and gastrointestinal cancers with positive KRAS inhibitor Phase 2 results
Time of Update: 2022-02-19
In a cohort of previously treated patients with pancreatic ductal adenocarcinoma and other gastrointestinal (GI) cancers harboring a KRAS G12C mutation, adagrasib demonstrated significant clinical activity and broad disease control .
References:[1] Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers.
-
Express Improves the Efficacy of Immune Checkpoint Inhibitors, Innovative Cancer Vaccine Enters Phase 2/3 Clinical Trials
Time of Update: 2022-01-24
"Reference: [1] Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC).
-
NRG Oncology Non-Small Cell Lung Cancer Trial has completed Phase 2 and data analysis is in progress to determine the restart of Phase 3
Time of Update: 2022-01-02
If the trial restarts, the question of the third phase of the study will examine whether adding LCT to maintenance system therapy can improve the overall survival of patients with limited metastatic NSCLC .
-
Phase 1/2 clinical trial of nitric oxide synthase inhibitor L-NMMA and taxane in the treatment of chemotherapy-resistant triple-negative breast cancer
Time of Update: 2021-12-27
Successful combinationA phase 1/2 clinical trial tested the effects of inducible nitric oxide synthase inhibitor (L-NMMA) combined with taxane in the treatment of refractory locally advanced breast cancer (LABC) and metastatic triple-negative breast cancer (TNBC) Curative effect .
-
Express 57% of bladder cancer patients have no recurrence in 12 months, and IL-15 super agonist reaches phase 2/3 clinical endpoint
Time of Update: 2021-11-04
▎ WuXi AppTec content team editor October 19, 2021, ImmunityBio announced that its IL-15 super agonist complex Anktiva (N-803) and BCG vaccine (BCG) combined with In the phase 2/3 clinical trial of NMIBC, the primary end point for the treatment of patients with papilloma subtypes was reached, and 57% of patients reached 12-month disease-free survival (DFS) .
-
or gastroesophageal junction cancer: 2-year updated results of phase III clinical study KEYNOTE-061
Time of Update: 2021-09-18
In patients with PD-L1 CPS ≥ 10, the median PFS of the pembrolizumab group and paclitaxel group were 2.
In patients with PD-L1 CPS ≥ 10, the median PFS of the pembrolizumab group and paclitaxel group were 2.
